Phase 1 Type 2 Diabetes Trial, Recruiting NCT07242469 Sponsor: Merck Sharp & Dohme LLC Condition: Type 2 Diabetes
Back to Type 2 Diabetes

Phase 1 Type 2 Diabetes Trial, Recruiting

NCT07242469
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with Type 2 diabetes mellitus (T2DM)
  • People whose Body Mass Index (BMI) falls between 18 and 40 kg/m², inclusive (BMI is a measure based on height and weight)

Who may not be able to join:

  • People who have Type 1 diabetes or other forms of diabetes that are caused by another medical condition
  • People who have a history of severe heart failure (classified as NYHA Class 3 or 4, meaning significant limitations on physical activity)
  • People who have a history of heart attack, uncontrolled irregular heartbeats, heart bypass or similar heart procedures, chest pain from heart disease, unstable circulation problems in the limbs, or stroke
  • People who have a history of cancer
  • People whose blood tests show current or past infection with hepatitis B, hepatitis C, or HIV
  • People who have a history of stomach or digestive conditions that could affect how food or medication is absorbed, or who have had gastric bypass or similar weight-loss surgery

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Medical Director, Merck Sharp & Dohme LLC

Phone: 1-888-577-8839

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Registry
ClinicalTrials.gov
Start date
22 December 2025
Est. completion
28 August 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Number of participants who experience one or more adverse events (AE); Number of participants who discontinue study intervention due to adverse events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov